XTLB
XTL Biopharmaceuticals Ltd.
Set alert
- YTD
- -30.60%
- 1 year
- -62.73%
- Open
- 1.65
- Prev close
- 1.76
- Mkt cap
- 3.96M
- Vol
- 8.60K
- Avg vol
- 7.97K
- EPS
- -0.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.61
- High
- 1.69
- Forward P/E
- 0.00
- Beta
- 1.00
- Short ratio
- 3.35
- Inst. own
- 1.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 25, 2024
- 50-d avg
- 1.84
- 200-d avg
- 2.32
- 1y target
- 0.00
Key statistics
- Market cap
- 9.59M
- Enterprise value
- 782.33M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 352.00
- EPS (TTM)
- -0.03
- Beta
- 1.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 2.34M
- Total debt
- 0
- Return on equity
- -13.07%
- Shares outstanding
- 5.45M
- Short % of float
- 0.00%
- 50-day average
- 1.84
- 200-day average
- 2.32
Analyst view
Consensus: none
Next earnings
Dec 25, 2024
Expected Dec 25, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 25, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 3, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | 0.10 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 2015 | HC Wainwright & Co. | init | — | Buy |
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- xtlbio.com
News
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- XTL Receives Nasdaq Noncompliance Letter
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings
Your note
Sign in to keep a note on XTLB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Noked Israel Ltd. | 3.65% | 198,888 | 350.04K | Sep 29, 2024 |
| Morgan Stanley | 0.49% | 26,451 | 46.55K | Sep 29, 2024 |
| Rhumbline Advisers | 0.12% | 6,519 | 11.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.16% | 8,903 | 15.67K | Oct 30, 2024 |